NASDAQ:PRTO - Proteon Therapeutics Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Proteon Therapeutics Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $36.87 +0.62 (+1.71 %) (As of 02/16/2020 02:38 PM ET) Add Compare Today's Range$35.00Now: $36.87▼$39.5050-Day Range$0.36MA: $22.43▼$39.0052-Week Range$0.22Now: $36.87▼$3.94Volume23,733 shsAverage Volume1.11 million shsMarket Capitalization$817.74 millionP/E RatioN/ADividend YieldN/ABeta0.6 ProfileAnalyst RatingsAdvanced ChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Proteon Therapeutics, Inc, a late-stage biopharmaceutical company, focuses on the development of pharmaceuticals to address the needs of patients with renal and vascular disease. Its lead product candidate is vonapanitase, an investigational drug intended to enhance hemodialysis vascular access outcomes. The company develops vonapanitase, a recombinant human elastase, which has completed Phase II and Phase III clinical trials for patients with chronic kidney disease. Read More… Industry, Sector and Symbol Stock Exchange NASDAQ Industry Biological products, except diagnostic Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:PRTO Previous Symbol CUSIPN/A CIK1359931 Webhttp://www.proteontherapeutics.com/ Phone781-890-0102Debt Debt-to-Equity RatioN/A Current Ratio5.98 Quick Ratio5.98Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value($0.06) per share Price / Book-614.50Profitability EPS (Most Recent Fiscal Year)($1.15) Net Income$-20,730,000.00 Net MarginsN/A Return on EquityN/A Return on Assets-118.68%Miscellaneous Employees17 Outstanding Shares22,179,000Market Cap$817.74 million Next Earnings Date3/11/2020 (Estimated) OptionableNot Optionable Receive PRTO News and Ratings via Email Sign-up to receive the latest news and ratings for PRTO and its competitors with MarketBeat's FREE daily newsletter. NASDAQ:PRTO Rates by TradingView Proteon Therapeutics (NASDAQ:PRTO) Frequently Asked Questions What is Proteon Therapeutics' stock symbol? Proteon Therapeutics trades on the NASDAQ under the ticker symbol "PRTO." How were Proteon Therapeutics' earnings last quarter? Proteon Therapeutics Inc (NASDAQ:PRTO) posted its earnings results on Thursday, October, 31st. The biopharmaceutical company reported ($0.08) earnings per share for the quarter, topping the consensus estimate of ($0.09) by $0.01. View Proteon Therapeutics' Earnings History. When is Proteon Therapeutics' next earnings date? Proteon Therapeutics is scheduled to release their next quarterly earnings announcement on Wednesday, March 11th 2020. View Earnings Estimates for Proteon Therapeutics. What price target have analysts set for PRTO? 5 brokers have issued twelve-month price targets for Proteon Therapeutics' stock. Their forecasts range from $1.00 to $5.00. On average, they anticipate Proteon Therapeutics' stock price to reach $3.33 in the next twelve months. This suggests that the stock has a possible downside of 91.0%. View Analyst Price Targets for Proteon Therapeutics. What is the consensus analysts' recommendation for Proteon Therapeutics? 5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Proteon Therapeutics in the last year. There are currently 4 hold ratings and 1 buy rating for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Proteon Therapeutics. What are Wall Street analysts saying about Proteon Therapeutics stock? Here are some recent quotes from research analysts about Proteon Therapeutics stock: 1. According to Zacks Investment Research, "Proteon Therapeutics Inc. is a biopharmaceutical company. The Company is developing pharmaceuticals to address the medical needs of patients with kidney and vascular diseases. It is developing PRT-201, a recombinant human elastase, applied in a single treatment to the external surface of arteries and veins during an open surgical procedure or an endovascular intervention. Proteon Therapeutics Inc. is headquartered in Waltham, Mass. " (11/14/2019) 2. Maxim Group analysts commented, "Proteon announced that the second phase 3 study of vonapanitase failed to reach statistical significance on both co-primary endpoints; secondary patency and fistula use for hemodialysis. The company is evaluating its strategic options and has $16.5M in cash on the balance sheet. Shares are down sharply (~83%). We have removed vonapanitase from our model and are downgrading the shares to and removing our prior price target of $5.00 as the company explores its options." (3/28/2019) Has Proteon Therapeutics been receiving favorable news coverage? News articles about PRTO stock have been trending neutral on Sunday, according to InfoTrie Sentiment Analysis. The research firm rates the sentiment of news coverage by monitoring more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of negative five to five, with scores nearest to five being the most favorable. Proteon Therapeutics earned a news impact score of 0.2 on InfoTrie's scale. They also assigned news stories about the biopharmaceutical company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an effect on the company's share price in the near term. View News Stories for Proteon Therapeutics. Are investors shorting Proteon Therapeutics? Proteon Therapeutics saw a decline in short interest in the month of January. As of January 15th, there was short interest totalling 58,500 shares, a decline of 52.6% from the December 31st total of 123,400 shares. Based on an average daily trading volume, of 7,400 shares, the days-to-cover ratio is presently 7.9 days. Currently, 20.1% of the company's stock are sold short. View Proteon Therapeutics' Current Options Chain. Who are some of Proteon Therapeutics' key competitors? Some companies that are related to Proteon Therapeutics include Allogene Therapeutics (ALLO), Audentes Therapeutics (BOLD), Atara Biotherapeutics (ATRA), Avrobio (AVRO), Osiris Therapeutics (OSIR), AVITA MED LTD/S (AVMXY), Aptose Biosciences (APTO), Autolus Therapeutics (AUTL), Axcella Health (AXLA), Allena Pharmaceuticals (ALNA), BioCardia (BCDA), Vical (VICL), Aevi Genomic Medicine (GNMX) and Neuralstem (CUR). What other stocks do shareholders of Proteon Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Proteon Therapeutics investors own include Celgene (CELG), SCYNEXIS (SCYX), Synergy Pharmaceuticals (SGYP), Sierra Oncology (SRRA), Verastem (VSTM), vTv Therapeutics (VTVT), Agile Therapeutics (AGRX), Biocept (BIOC), Fate Therapeutics (FATE) and Idera Pharmaceuticals (IDRA). Who are Proteon Therapeutics' key executives? Proteon Therapeutics' management team includes the folowing people: Mr. Timothy P. Noyes, Pres, CEO & Director (Age 57)Mr. George A. Eldridge, Sr. VP, CFO, Treasurer & Assistant Sec. (Age 56)Dr. Steven Keith Burke, Sr. VP & Chief Medical Officer (Age 58)Mr. Matthew P. Kowalsky, VP of Legal & Sec. (Age 46)Mr. Bradley J. Hartman, VP of People (Age 38) Who are Proteon Therapeutics' major shareholders? Proteon Therapeutics' stock is owned by a variety of of retail and institutional investors. Top institutional investors include Abingworth LLP (9.67%), Renaissance Technologies LLC (3.81%), Perceptive Advisors LLC (1.54%), Fairmount Funds Management LLC (1.54%), Ikarian Capital LLC (1.52%) and Wedbush Securities Inc. (0.92%). View Institutional Ownership Trends for Proteon Therapeutics. Which major investors are selling Proteon Therapeutics stock? PRTO stock was sold by a variety of institutional investors in the last quarter, including UBS Group AG. View Insider Buying and Selling for Proteon Therapeutics. Which major investors are buying Proteon Therapeutics stock? PRTO stock was purchased by a variety of institutional investors in the last quarter, including Perceptive Advisors LLC, Fairmount Funds Management LLC, Ikarian Capital LLC, Abingworth LLP, Renaissance Technologies LLC and Wedbush Securities Inc.. View Insider Buying and Selling for Proteon Therapeutics. How do I buy shares of Proteon Therapeutics? Shares of PRTO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab. What is Proteon Therapeutics' stock price today? One share of PRTO stock can currently be purchased for approximately $36.87. How big of a company is Proteon Therapeutics? Proteon Therapeutics has a market capitalization of $817.74 million. The biopharmaceutical company earns $-20,730,000.00 in net income (profit) each year or ($1.15) on an earnings per share basis. Proteon Therapeutics employs 17 workers across the globe.View Additional Information About Proteon Therapeutics. What is Proteon Therapeutics' official website? The official website for Proteon Therapeutics is http://www.proteontherapeutics.com/. How can I contact Proteon Therapeutics? Proteon Therapeutics' mailing address is 200 WEST STREET, WALTHAM MA, 02451. The biopharmaceutical company can be reached via phone at 781-890-0102 or via email at [email protected] MarketBeat Community Rating for Proteon Therapeutics (NASDAQ PRTO)Community Ranking: 2.6 out of 5 ( )Outperform Votes: 267 (Vote Outperform)Underperform Votes: 239 (Vote Underperform)Total Votes: 506MarketBeat's community ratings are surveys of what our community members think about Proteon Therapeutics and other stocks. Vote "Outperform" if you believe PRTO will outperform the S&P 500 over the long term. Vote "Underperform" if you believe PRTO will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 2/16/2020 by MarketBeat.com StaffFeatured Article: What is the accumulation/distribution indicator?
